CADTH recommends that Welireg should be reimbursed by public drug plans for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated nonmetastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or nonmetastatic pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery if certain conditions are met.
Welireg should only be covered to treat adult patients with VHL disease who require therapy for associated nonmetastatic RCC, CNS hemangioblastomas, or nonmetastatic pNET, not requiring immediate surgery. Patients receiving Welireg should be in relatively good health.
Welireg should only be reimbursed if it is prescribed by specialists with expertise in VHL disease-associated tumours and if the cost of Welireg is reduced. Welireg should not be used in combination with other anti-tumour drugs.
{"title":"Belzutifan (Welireg)","authors":"None CADTH","doi":"10.51731/cjht.2023.742","DOIUrl":"https://doi.org/10.51731/cjht.2023.742","url":null,"abstract":"
 CADTH recommends that Welireg should be reimbursed by public drug plans for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated nonmetastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or nonmetastatic pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery if certain conditions are met.
 Welireg should only be covered to treat adult patients with VHL disease who require therapy for associated nonmetastatic RCC, CNS hemangioblastomas, or nonmetastatic pNET, not requiring immediate surgery. Patients receiving Welireg should be in relatively good health.
 Welireg should only be reimbursed if it is prescribed by specialists with expertise in VHL disease-associated tumours and if the cost of Welireg is reduced. Welireg should not be used in combination with other anti-tumour drugs.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136375819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical evidence showed that treatment with glecaprevir-pibrentasvir for children and adolescents with chronic hepatitis C virus infection was efficacious with an overall sustained virologic response 12 weeks after treatment near 100%. Glecaprevir-pibrentasvir treatment was well-tolerated as there were no serious adverse events or adverse events leading to treatment discontinuation. Most adverse events were mild. We did not find any studies that evaluated the cost-effectiveness of glecaprevir-pibrentasvir for the treatment of chronic hepatitis C virus infection in pediatric patients. We did not find any peer-reviewed studies that evaluated the clinical effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients. Unpublished data in a conference abstract and clinical trial registry suggest effectiveness of sofosbuvir-velpatasvir, but the findings should be interpreted with cautions. We did not find any studies that evaluated the cost-effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients.
{"title":"Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection","authors":"Khai Tran, Kendra Brett, Melissa Walter","doi":"10.51731/cjht.2023.740","DOIUrl":"https://doi.org/10.51731/cjht.2023.740","url":null,"abstract":"Clinical evidence showed that treatment with glecaprevir-pibrentasvir for children and adolescents with chronic hepatitis C virus infection was efficacious with an overall sustained virologic response 12 weeks after treatment near 100%. \u0000Glecaprevir-pibrentasvir treatment was well-tolerated as there were no serious adverse events or adverse events leading to treatment discontinuation. Most adverse events were mild. \u0000We did not find any studies that evaluated the cost-effectiveness of glecaprevir-pibrentasvir for the treatment of chronic hepatitis C virus infection in pediatric patients. \u0000We did not find any peer-reviewed studies that evaluated the clinical effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients. Unpublished data in a conference abstract and clinical trial registry suggest effectiveness of sofosbuvir-velpatasvir, but the findings should be interpreted with cautions. \u0000We did not find any studies that evaluated the cost-effectiveness of sofosbuvir-velpatasvir for the treatment of chronic hepatitis C virus infection in pediatric patients.","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"154 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135063786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A shortage of iodinated contrast media (ICM) used in contrast-enhanced CT exams led to the adoption of necessary conservation strategies across Canada.
Conservation strategies included multidispensing from single-use and multiuse ICM bottles, diluting or reducing ICM dose volumes, switching to weight-based dosing from fixed-based dosing, lower tube voltage, performing unenhanced CT scans, using alternative imaging modalities, or prioritizing urgent cases. One of the more common alternative conservation strategies was to prioritize urgent cases for contrast-enhanced CT exams.
Most medical imaging staff who responded to a national survey on ICM conservation strategies reported they would return to their regular doses used before the shortage despite little to no perceived effect on the contrast conspicuity of images or on patient adverse events with reduced ICM volumes.
The ICM shortage represents an opportunity to reconsider ICM usage practices given environmental sustainability concerns with ICM and potential cost savings in reducing its use.
{"title":"Optimizing the Use of Iodinated Contrast Media: Conservation Strategies Used Across Canada During the 2022 Shortage","authors":"None CADTH","doi":"10.51731/cjht.2023.739","DOIUrl":"https://doi.org/10.51731/cjht.2023.739","url":null,"abstract":"
 A shortage of iodinated contrast media (ICM) used in contrast-enhanced CT exams led to the adoption of necessary conservation strategies across Canada.
 Conservation strategies included multidispensing from single-use and multiuse ICM bottles, diluting or reducing ICM dose volumes, switching to weight-based dosing from fixed-based dosing, lower tube voltage, performing unenhanced CT scans, using alternative imaging modalities, or prioritizing urgent cases. One of the more common alternative conservation strategies was to prioritize urgent cases for contrast-enhanced CT exams.
 Most medical imaging staff who responded to a national survey on ICM conservation strategies reported they would return to their regular doses used before the shortage despite little to no perceived effect on the contrast conspicuity of images or on patient adverse events with reduced ICM volumes.
 The ICM shortage represents an opportunity to reconsider ICM usage practices given environmental sustainability concerns with ICM and potential cost savings in reducing its use.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135063989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Midline catheters may be associated with longer uncomplicated indwelling time and a lower overall risk of catheter-related complications than extended dwell catheters.
The rates of catheter-related complications were low across different peripheral catheter types.
Midline catheters may have a lower proportion of catheter-related bloodstream infections, drug leakage from the exit site, and complete catheter occlusion, but a higher proportion of catheter-related thrombosis events compared with extended dwell catheters.
The findings were derived from 1 retrospective cohort study with imbalanced baseline characteristics of patients, and the limitations of the study may have favoured midline catheters; future studies are needed to confirm our findings.
We did not find any systematic reviews, health technology assessments, randomized controlled trials, or evidence-based guidelines that met our inclusion criteria.
{"title":"Midline and Extended Dwell Catheters for IV Antibiotics","authors":"Qiukui Hao, Jennifer Horton","doi":"10.51731/cjht.2023.738","DOIUrl":"https://doi.org/10.51731/cjht.2023.738","url":null,"abstract":"
 Midline catheters may be associated with longer uncomplicated indwelling time and a lower overall risk of catheter-related complications than extended dwell catheters.
 The rates of catheter-related complications were low across different peripheral catheter types.
 Midline catheters may have a lower proportion of catheter-related bloodstream infections, drug leakage from the exit site, and complete catheter occlusion, but a higher proportion of catheter-related thrombosis events compared with extended dwell catheters.
 The findings were derived from 1 retrospective cohort study with imbalanced baseline characteristics of patients, and the limitations of the study may have favoured midline catheters; future studies are needed to confirm our findings.
 We did not find any systematic reviews, health technology assessments, randomized controlled trials, or evidence-based guidelines that met our inclusion criteria.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135436401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses Foslevodopa-foscarbidopa (Vyalev), 240 mg/mL foslevodopa and 12 mg/mL foscarbidopa solution, subcutaneous infusion.
Indication: For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper- /dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products.
{"title":"Foslevodopa-Foscarbidopa (Vyalev)","authors":"None CADTH","doi":"10.51731/cjht.2023.737","DOIUrl":"https://doi.org/10.51731/cjht.2023.737","url":null,"abstract":"
 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses Foslevodopa-foscarbidopa (Vyalev), 240 mg/mL foslevodopa and 12 mg/mL foscarbidopa solution, subcutaneous infusion.
 Indication: For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper- /dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135785933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
For children with short stature who were born small for gestational age, 1 guideline suggests increasing human growth hormone dose when treatment response is unsatisfactory, while aiming for normal insulin-like growth factor 1 levels.
For children with idiopathic short stature, 1 guideline recommends against the routine use of growth hormone. It suggests initiating growth hormone therapy on a case-by-case basis, with a starting dose ranging from 0.24 mg/kg/week to 0.47 mg/kg/week, as well as conducting an assessment 12 months after initiation to optimize dosage.
The development of recommendations from guidelines included in this report was challenged by limited relevant evidence, as well as heterogeneity of growth hormone dose and frequency and treatment response found in available literature. Future guidelines should also consider patient perspectives, resource implications, and the facilitators of and barriers to therapy within the context of health care systems in Canada.
{"title":"Somatropin for Short Stature","authors":"Camille Santos, Jennifer Horton","doi":"10.51731/cjht.2023.736","DOIUrl":"https://doi.org/10.51731/cjht.2023.736","url":null,"abstract":"
 For children with short stature who were born small for gestational age, 1 guideline suggests increasing human growth hormone dose when treatment response is unsatisfactory, while aiming for normal insulin-like growth factor 1 levels.
 For children with idiopathic short stature, 1 guideline recommends against the routine use of growth hormone. It suggests initiating growth hormone therapy on a case-by-case basis, with a starting dose ranging from 0.24 mg/kg/week to 0.47 mg/kg/week, as well as conducting an assessment 12 months after initiation to optimize dosage.
 The development of recommendations from guidelines included in this report was challenged by limited relevant evidence, as well as heterogeneity of growth hormone dose and frequency and treatment response found in available literature. Future guidelines should also consider patient perspectives, resource implications, and the facilitators of and barriers to therapy within the context of health care systems in Canada.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135784917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In acute care settings with low-risk of infection transmission, discontinuing contact precautions (i.e., gloves and gown) may result in similar rates of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and may lower the risk of hospital-acquired vancomycin-resistant enterococci (VRE), compared to scenarios in which such precautions were employed. Rates of late-onset infections in a neonatal intensive care unit were similar when standard infection control precautions were used compared with universal glove use. Two guidelines recommend that nonsterile gloves should be worn for nonsterile procedures when it is anticipated that there will be contact with blood, body fluids, non-intact skin, mucous membranes, lesions, or hazardous drugs and chemicals; for environmental cleaning; and when contact precautions for infection control are in effect.
{"title":"Nonsterile Glove Use","authors":"Gabrielle Brankston, Sharon Bailey","doi":"10.51731/cjht.2023.735","DOIUrl":"https://doi.org/10.51731/cjht.2023.735","url":null,"abstract":"In acute care settings with low-risk of infection transmission, discontinuing contact precautions (i.e., gloves and gown) may result in similar rates of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and may lower the risk of hospital-acquired vancomycin-resistant enterococci (VRE), compared to scenarios in which such precautions were employed. Rates of late-onset infections in a neonatal intensive care unit were similar when standard infection control precautions were used compared with universal glove use. Two guidelines recommend that nonsterile gloves should be worn for nonsterile procedures when it is anticipated that there will be contact with blood, body fluids, non-intact skin, mucous membranes, lesions, or hazardous drugs and chemicals; for environmental cleaning; and when contact precautions for infection control are in effect.","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135885779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses trastuzumab deruxtecan (Enhertu),100 mg, powder for solution for IV infusion.
Indication: For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH−) breast cancer who have received at least 1 prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; patients with HR-positive breast cancer should have received at least 1 line of endocrine therapy and be no longer considered for endocrine therapy.
{"title":"Trastuzumab deruxtecan (Enhertu)","authors":"None CADTH","doi":"10.51731/cjht.2023.734","DOIUrl":"https://doi.org/10.51731/cjht.2023.734","url":null,"abstract":"
 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses trastuzumab deruxtecan (Enhertu),100 mg, powder for solution for IV infusion.
 Indication: For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH−) breast cancer who have received at least 1 prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; patients with HR-positive breast cancer should have received at least 1 line of endocrine therapy and be no longer considered for endocrine therapy.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"70 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136024393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH recommends that Xcopri should be reimbursed by public drug plans as adjunctive therapy in the management of partial onset seizures in adults with epilepsy whose seizures are not satisfactorily controlled with conventional therapy, if certain conditions are met.
Xcopri should only be reimbursed for the management of partial onset seizures in adults with epilepsy whose seizures are not satisfactorily controlled with conventional therapy, according to the criteria used by the public drug plans for other third generation antiseizure medication (ASMs) that are currently reimbursed for the management of partial onset seizures in adults with epilepsy whose seizures are not satisfactorily controlled with conventional therapy.
Xcopri should only be reimbursed if the daily cost of Xcopri is the same as or lower than the daily cost of other third generation adjunctive therapies (lacosamide, brivaracetam, eslicarbazepine, and perampanel), and if the potential budget impact of funding Xcopri is addressed.
{"title":"Cenobamate (Xcopri)","authors":"None CADTH","doi":"10.51731/cjht.2023.733","DOIUrl":"https://doi.org/10.51731/cjht.2023.733","url":null,"abstract":"
 CADTH recommends that Xcopri should be reimbursed by public drug plans as adjunctive therapy in the management of partial onset seizures in adults with epilepsy whose seizures are not satisfactorily controlled with conventional therapy, if certain conditions are met.
 Xcopri should only be reimbursed for the management of partial onset seizures in adults with epilepsy whose seizures are not satisfactorily controlled with conventional therapy, according to the criteria used by the public drug plans for other third generation antiseizure medication (ASMs) that are currently reimbursed for the management of partial onset seizures in adults with epilepsy whose seizures are not satisfactorily controlled with conventional therapy.
 Xcopri should only be reimbursed if the daily cost of Xcopri is the same as or lower than the daily cost of other third generation adjunctive therapies (lacosamide, brivaracetam, eslicarbazepine, and perampanel), and if the potential budget impact of funding Xcopri is addressed.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136024399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses dapagliflozin propanediol monohydrate 10 mg oral tablet.
Indication: To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease.
{"title":"Dapagliflozin","authors":"None CADTH","doi":"10.51731/cjht.2023.732","DOIUrl":"https://doi.org/10.51731/cjht.2023.732","url":null,"abstract":"
 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses dapagliflozin propanediol monohydrate 10 mg oral tablet.
 Indication: To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136362627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：